Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
about
Polyunsaturated fatty acid metabolism in prostate cancerHeparan sulphate synthetic and editing enzymes in ovarian cancerSyndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and PrognosticationMolecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicineThe role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagyInsidious changes in stromal matrix fuel cancer progressionHeparan sulfate signaling in cancerLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.The Extracellular Matrix in Epithelial Ovarian Cancer - A Piece of a Puzzle.The role of the tumor stroma in ovarian cancer.Endogenous synthesis of n-3 polyunsaturated fatty acids in Fat-1 mice is associated with increased mammary gland and liver syndecan-1.The motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans.Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancerDcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2.Syndecan-1 (CD 138) surface expression marks cell type and differentiation in ameloblastoma, keratocystic odontogenic tumor, and dentigerous cyst.Decidualization and syndecan-1 knock down sensitize endometrial stromal cells to apoptosis induced by embryonic stimuliPrognostic significance of syndecan-1 expression in cervical cancers.Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.Toward an integrative analysis of the tumor microenvironment in ovarian epithelial carcinoma.ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal CarcinomatosisSuperficial spreading squamous cell carcinoma of the uterine cervix involving the endometrium: Report of two cases with emphasis on the likely molecular mechanismPrognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.Differential expression of syndecans and glypicans in chronically inflamed synovium.Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma.Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions.Proteoglycans in prostate cancer.Targeting syndecans: a promising strategy for the treatment of cancer.Syndecan-1 knockdown in endometrial epithelial cells alters their apoptotic protein profile and enhances the inducibility of apoptosis.Shed proteoglycans in tumor stroma.Sdc1 negatively modulates carcinoma cell motility and invasion.Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy.Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells.Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma.Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.Syndecan-1 regulates adipogenesis: new insights in dedifferentiated liposarcoma tumorigenesis.Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression
P2860
Q24629893-D3DB195F-9614-4FC6-91C9-80FE6C3A9748Q24653774-4E82EC4C-1E51-4035-81A8-FE2B48DBFBBFQ26784262-BD462326-FB1C-4A6A-AE9D-E3BC257BFE89Q26796247-7B80ACF3-8540-4BD6-A26C-387519BBCFCFQ26800258-6C8FAB69-6560-4229-ABE5-4738C3C282C8Q26851261-825066EA-A6B7-4833-8348-2631C969D567Q28657828-354C4FA2-C976-4279-8D4B-2D02C6673BB4Q30366990-AEA59608-A798-4EB1-9EDA-B1000CBE503FQ33361929-4625D2D8-7203-495D-94A8-B9DC475E7546Q33633856-4653398C-4256-48D0-8865-DDCD7A491F6CQ33927026-15021936-5825-440A-BB40-D9A7A9317D1DQ34031745-72FD5ADB-F2DE-4282-8CC3-391DA37A6598Q34177237-550FC949-F820-42F8-A8C2-8415786178C4Q34268238-216BA197-BDE0-4D85-A08A-6982ABCE83BEQ34321430-E0E28A32-2F2E-4D16-99B4-86633A755E01Q34322029-A627D1E3-DF43-430F-8419-71B6C6FCDF90Q35243043-FF30C706-D957-4C00-8AFF-30889B234FF1Q35285294-E5AA0E1C-300D-4907-AD3D-67C07F66F0A9Q35768137-2285DECE-9611-4D34-8080-2CED67E423DDQ36101228-57456811-1E4F-49A0-80F3-0C1E3724B417Q36235795-788D39AF-173E-4002-8A3D-1155AB2E2974Q36387694-331BB7D0-754B-45D4-AF93-2BE1B2493220Q36475802-453AC22A-7906-49CC-926B-7F4CBD0BA890Q36769318-A4F79B09-D479-40A5-9AB4-90E03A4DD406Q36787608-8989F8F4-88E0-42E2-830C-192FEE231720Q36927550-F1B4B0BA-14F9-436D-8FAA-57C6765A1B31Q37525296-CA9C408C-ED2B-4582-9F6E-3C5549DD21E0Q37636855-D7FEACA2-9CD1-4588-81C9-BCA8144F49E1Q37986399-2063F965-A030-4482-BF24-37C3F53A41B0Q38082795-E61BB560-DDFF-40C4-945D-04DE9377B30DQ38309339-2ED4E15F-DF1D-438C-B1C1-484F94B36F3EQ38882752-72D05596-9FCB-4F69-8EFB-62F4B23D8804Q39494666-8C771DED-24C5-434E-BBA5-04791B5FE0BCQ40063020-BB72F565-EC1B-4253-BC1C-91EED4146A16Q40297851-BF495ADE-4DA2-4B5A-89B1-B954B0D1CBF3Q45351456-A9650ABA-9003-4E5C-B4DD-5F1C48F43197Q48923743-1E94C9C1-5977-41D2-B4D9-5BEAA7B48AA1Q51040058-2ED9DB3A-C557-49CE-A9BF-1214311BC92CQ52714362-E14B695D-EC39-468A-96BE-8C19C72F3298Q58705289-FCAAD68F-4C6B-4A3D-84FC-FE32F1DE7FC5
P2860
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@ast
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@en
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@nl
type
label
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@ast
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@en
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@nl
prefLabel
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@ast
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@en
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@nl
P2093
P3181
P1476
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
@en
P2093
Alan T McGown
E June Davies
Fiona H Blackhall
Gordon C Jayson
Guido David
John T Gallagher
Jonathan H Shanks
Pierre Martin-Hirsch
Ric Swindell
Richard J Slade
P304
P3181
P356
10.1158/1078-0432.CCR-03-0103
P407
P577
2004-08-01T00:00:00Z